The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4+ T cells and secrete gamma interferon after coapplication onto bare skin

Infection and Immunity

Volumn 70, Issue 6, 2002, Pages 3012-3019

  Beignon, A S ^a   Briand, J P ^a   Rappuoli, R ^a   Muller, S ^a   Partidos, C D ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ESCHERICHIA COLI ENTEROTOXIN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; LTR63 TOXIN; LTR72 TOXIN; SYNTHETIC PEPTIDE; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENTEROTOXINS; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MUTAGENESIS; NUCLEOPROTEINS; PEPTIDES; RNA-BINDING PROTEINS; SKIN; TETANUS TOXIN; VACCINATION; VIRAL CORE PROTEINS;

EID: 0036259810     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.6.3012-3019.2002     Document Type: Article

References (38)

1. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge
2. + T cells
3. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protect mice against Toxoplasma gondii
4. The skin immune system: Its cellular constituents and their interactions
5. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)
6. Genetically derived toxoids for use as vaccines and adjuvants
7. Delinetion of several DR restricted tetanus toxin T-cell epitopes
8. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin:Alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity
9. T-cell growth factor: Parameters of production and a quantitative microassay for activity
10. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
11. Skin immunization made possible by cholera toxin
12. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
13. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
14. Transcutaneous immunization: A human vaccine delivery strategy using a patch
15. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin
16. Transcutaneous immunization: An emerging route of immunization and potent immunostimulation strategy
17. Mechanisms of resistance to S. mansoni infection: The rat model
18. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
19. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines
20. CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G)
21. Laboratory protocols for the identification of Th cell epitopes on self-antigens in mice with systemic autoimmune diseases J
22. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
23. Potent immunogenicity of the B subunit of Escherichia coli heat-labile enterotoxin: Receptor binding is esential and induces differential modulation of lymphocyte subsets
24. Anti-peptide antibody responses following intranasal immunization: Effectiveness of mucosal adjuvants
25. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs
26. Intranasal vaccines: Forthcoming challenges
27. The bare skin and the nose as non-invasive routes for administering peptide vaccines
28. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials
29. Mucosal vaccines: Nontoxic derivatives of LT and CT as mucosal adjuvants
30. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
31. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
32. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: Distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity
33. IgE sensitization to gelatin: The probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines
34. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants
35. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin
36. Immunity at the surface: Homeostatic mechanisms of the skin immune system
37. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
38. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant